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STUDY QUESTION:What progress has been made in fertility preservation (FP) over the last decade?
SUMMARY ANSWER: FP techniques have been widely adopted over the last decade and therefore the establishment of international
registries on their short- and long-term outcomes is strongly recommended.
WHAT IS KNOWN ALREADY: FP is a fundamental issue for both males and females whose future fertility may be compromised.
Reproductive capacity may be seriously affected by age, different medical conditions and also by treatments, especially those with gonadal
toxicity. There is general consensus on the need to provide counselling about currently available FP options to all individuals wishing to pre-
serve their fertility.
STUDY DESIGN, SIZE, DURATION: An international meeting with representatives from expert scientiﬁc societies involved in FP was
held in Barcelona, Spain, in June 2015.
PARTICIPANTS/MATERIALS, SETTING, METHODS: Twenty international FP experts belonging to the American Society of
Reproductive Medicine, ESHRE and the International Society of Fertility Preservation reviewed the literature up to June 2015 to be discussed
at the meeting, and approved the ﬁnal manuscript. At the time this manuscript was being written, new evidence considered relevant for the
debated topics was published, and was consequently included.
MAIN RESULTS AND THE ROLE OF CHANCE: Several oncological and non-oncological diseases may affect current or future fertility,
either caused by the disease itself or the gonadotoxic treatment, and need an adequate FP approach. Women wishing to postpone maternity
and transgender individuals before starting hormone therapy or undergoing surgery to remove/alter their reproductive organs should also be
counselled accordingly. Embryo and oocyte cryopreservation are ﬁrst-line FP methods in post-pubertal women. Metaphase II oocyte cryopreser-
vation (vitriﬁcation) is the preferred option. Cumulative evidence of restoration of ovarian function and spontaneous pregnancies after ART fol-
lowing orthotopic transplantation of cryopreserved ovarian tissue supports its future consideration as an open clinical application. Semen
cryopreservation is the only established method for FP in men. Testicular tissue cryopreservation should be recommended in pre-pubertal boys
even though fertility restoration strategies by autotransplantation of cryopreserved testicular tissue have not yet been tested for safe clinical use
in humans. The establishment of international registries on the short- and long-term outcomes of FP techniques is strongly recommended.
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LIMITATIONS, REASONS FOR CAUTION: Given the lack of studies in large cohorts or with a randomized design, the level of evidence
for most of the evidence reviewed was three or below.
WIDER IMPLICATIONS OF THE FINDINGS: Further high quality studies are needed to study the long-term outcomes of FP
techniques.
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Introduction
Reproductive capacity may be seriously affected by age, different condi-
tions, including genetic syndromes, and also by treatments, especially those
with gonadal toxicity. Fertility preservation (FP) is a fundamental issue for
individuals of reproductive age, both male and female, or prepubescent
boys and girls whose future fertility may be compromised. There is general
consensus on the need to provide counselling about currently available FP
options to all individuals wishing to preserve their fertility. Timely referral
to a fertility specialist for informed FP decisions becomes essential.
Several techniques for FP are nowadays well established while others
are still considered experimental. These techniques have been the sub-
ject of continuous review by experts with the aim of providing physicians
involved in FP with up-to-date knowledge and counselling. Given the
particular nature of FP, recommendations are largely based on cohort
studies, case series, small non-randomized clinical trials, or case reports,
which further makes FP a challenging but rather controversial ﬁeld.
Reviews have been mostly focused on cancer, which is probably the
main indication for FP given its high incidence and impact on repro-
ductive health (ISFP Practice Committee et al., 2012; Ethics
Committee of ASRM, 2013; Loren et al., 2013; Oktay and Rodriguez-
Wallberg, 2014; Mahajan, 2015; Lambertini et al., 2016). However,
the need for FP in other pathologic situations, either due to the disease
itself or to gonadotoxic treatment, and even in non-medical indica-
tions, is on the rise. Moreover, new perspectives to tackle FP are being
developed, and evidence about the results of spontaneous pregnancy
and ART after current FP procedures is growing, which may further
help clinicians provide adequate counselling. With the aim of reviewing
all these aspects and drawing recommendations, an international
meeting with representatives from expert scientiﬁc societies involved
in FP was held in Barcelona (Spain) in June 2015. This paper sum-
marizes the topics debated, with a special focus on indications for FP,
current outcomes and future perspectives. A condensed version of
this summary has been included in the print issue of Human
Reproduction.
Materials andMethods
Twenty international FP experts belonging to the American Society of
Reproductive Medicine (ASRM), ESHRE and the International Society of
Fertility Preservation (ISFP) attended the meeting. Experts conducted a
review of the literature and evidence presented in scientiﬁc meetings up to
June 2015 to be discussed at the meeting. At the time this manuscript was
being written, new evidence considered relevant for the debated topics
was published, and has consequently been included. Given the lack of stud-
ies in large cohorts or with a randomized design, the quality of evidence
according to the European Society for Medical Oncology Clinical Practice
Guidelines for fertility preservation in cancer patients (Lambertini et al.,
2016) for most of the evidence reviewed was three or below.
Indications for FP
Cancer
Many forms of cancer are associated with impaired semen quality or
ovarian function at the time of cancer diagnosis. However, the main
effect on fertility arises from commonly used treatments such as
chemotherapy with alkylating agents and pelvic radiation that present
well-known gonadotoxic side effects. Gonadal failure resulting from
these treatments may affect different aspects of reproductive health,
including pubertal development, hormone production, and sexual
function in adults (Oktay and Rodriguez-Wallberg, 2014; Picton et al.,
2015). The fact that more than 80% of children and adolescents with
cancer become long-term survivors (Phillips et al., 2015) has raised an
increased interest in the long-term effects of cancer treatment on
fertility.
Male
Spermatogonia are especially sensitive to chemotherapy and radio-
therapy. The effect, which is dose-dependent, may not be permanent
if the spermatogonial stem cell (SSC) population is not fully depleted
(Oktay and Rodriguez-Wallberg, 2014). Data about the impact of
recent biological or targeted cancer therapies on male fertility are lim-
ited (Loren et al., 2013). For most of these therapies, the effects seem
to be mild, mostly involving reproductive endocrinology (Meistrich,
2013). Finally, surgical pelvic interventions for malignant or benign dis-
ease may affect the anatomy or normal functioning of reproductive
organs (Levine, 2014).
Female
Chemotherapy and radiotherapy may induce premature ovarian insuf-
ﬁciency (POI) in women (Donnez and Dolmans, 2013). Ovarian dam-
age is drug- and dose-dependent and increases as the patient ages
(Ethics Committee of ASRM, 2013). Radiotherapy may also affect the
uterus, leading to reduced vascularity, myometrium damage (ﬁbrosis)
and hormone-dependent insufﬁciency (Mahajan, 2015). Recent evi-
dence in female survivors of childhood cancer shows that chemother-
apy without radiotherapy to the brain or the pelvis has few effects on
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future pregnancy or live births (Chow et al., 2016). In any case, FP
should be considered prior to chemotherapy to maximize future
reproductive potential. Data about the impact of recent biological or
targeted cancer female fertility therapies is also limited except for bev-
acizumab, with a 34% rate of POI reported (Loren et al., 2013).
Fertility may also be impaired by surgical removal or damage to repro-
ductive organs.
Non-oncological medical indications
FP options should also be discussed with adult and younger women
and men affected by several non-oncological medical conditions. Non-
oncological systemic diseases, such as haematological and autoimmune
conditions, usually require chemotherapy or radiotherapy, especially
for those in need of a bone marrow or haematopoietic stem cell trans-
plantation (HSCT) (Donnez and Dolmans, 2013). In other conditions
reproductive function may be compromised by genetic causes or by
surgical interventions. Finally, FP may be offered to patients at high risk
of fertility loss as a result of severe body trauma requiring surgical
intervention. Table I summarizes the most common non-oncological
conditions requiring FP.
Autoimmune diseases
Table I summarizes autoimmune diseases reported to beneﬁt from
immunosuppressive therapy with alkylating agents (cyclophosphamide)
(Donnez and Dolmans, 2013; Bedaiwy and Botros, 2014). POI in these
women is also affected by disease duration and presence of anti-Ro
and anti-U1RNP (ribonucleoprotein) antibodies (Harward et al.,
2013). Continuous POI in women with chronic autoimmune diseases
also increases the risk of hypoestrogenism-related comorbidities
(including cardiovascular disease and osteoporosis) (Marder et al.,
2012). Males with systemic lupus erythematosus show a high fre-
quency of testicular Sertoli cell dysfunction associated with semen
abnormalities (Suehiro et al., 2008). New treatment approaches are
changing the prognosis of patients with autoimmune diseases, although
information about toxicity for reproduction is still limited.
Hematopoietic stem cell transplantation
HSCT (autologous or allogeneic) has been an important therapeutic
tool for some oncological and non-oncological systemic diseases.
Patients undergoing HSCT are at particularly high risk of developing
ovarian (64–85%) or testicular (50–90%) failure since aggressive
chemotherapy and radiotherapy is needed to destroy pre-existing
bone marrow (Joshi et al., 2014).The most common non-oncological
diseases beneﬁting from HSTC are autoimmune diseases that are
unresponsive to immunosuppressive therapy or benign haematological
diseases (Table I) (Donnez and Dolmans, 2013).
Medical conditions causing POI
POI may also result from several other causes, including an altered
hypothalamic–pituitary–gonadal axis, ovarian oophoritis, benign ovar-
ian tumours, either due to their extensive or progressive nature, or
bilateral adnexectomy (Donnez and Kim, 2011; Harward et al., 2013).
POI is also common in Turner’s syndrome. However, FP may not be
feasible for most patients with this disease since by the time they reach
puberty their primordial follicle reserve may already be depleted. FP
may only be offered to young patients with mosaic Turner’s syndrome
.............................................................................................................................................................................................
Table I Non-oncological conditions requiring fertility preservation.
Indication Disease
Autoimmune diseases (Donnez and Dolmans, 2013; Bedaiwy
and Botros, 2014)
Systemic lupus erythematosus (SLE)
Behcet’s disease
Churg-Strauss syndrome (eosinophilic granulomatosis)
Steroid resistant glomerulonephritis
Granulomatosis with polyangiitis (formerly Wegener’s granulomatosis)
Inﬂammatory bowel diseases
Rheumatoid arthritis
Pemphigus vulgaris
Hematopoietic stem cell transplantation (Donnez and Dolmans, 2013,
Joshi et al., 2014)
Autoimmune diseases unresponsive to immunosuppressive therapy
Haematological diseases (sickle cell anaemia, thalassaemia major, plastic anaemia)
Medical conditions causing POI (ESHRE POI Guideline Development
Group, 2015)
Altered hypothalamic–pituitary–gonadal axis (Donnez and Kim, 2011, Harward et al.,
2013)
Ovarian oophoritis
Benign ovarian tumours
Mosaic Turner’s syndrome
Fragile X Mental Retardation 1 (Gleicher et al., 2015)
Galactosemia (Fridovich-Keil et al., 2011)
Beta-thalassaemia (Roussou et al., 2013)
Endometriosis (Somigliana et al., 2015)
Male genetic disorders Klinefelter’s syndrome (Bedaiwy and Botros, 2014)
Testicular damage (Stahl et al., 2010)
Gender reassignment procedures (Darney, 2008)
Severe body trauma requiring surgical intervention
POI, premature ovarian insufﬁciency.
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after careful consideration of increased pregnancy-associated risks
(Lau et al., 2009; ESHRE POI Guideline Development Group, 2015).
Other conditions associated with POI include FMR1 gene mutations
(Fragile X Mental Retardation 1) as a result of premature ovarian aging
(Gleicher et al., 2015), classic galactosemia (Fridovich-Keil et al., 2011)
or beta-thalassaemia in female patients who suffer from hypogonado-
trophic hypogonadism associated with amenorrhoea, anovulation and
infertility (Roussou et al., 2013).
It is well documented that women with endometriosis are at
increased risk of POI and that about half of them will experience infer-
tility (Somigliana et al., 2015). The causal relationship between endo-
metriosis and infertility is unclear (Practice Committee of the ASRM,
2012). FP may be of interest for reproductive-age women at risk of
impaired fertility due to progression or surgical treatment of this condi-
tion (Bedoschi et al., 2013). Nevertheless, some authors restrict FP to
women with bilateral unoperated endometriomas and those with pre-
vious unilateral endometriomaremoval requiring surgery for a contra-
lateral recurrence (Somigliana et al., 2015).
Male genetic disorders and testicular tissue damage
Klinefelter’s syndrome is the most common sex chromosomal dis-
order in humans. This syndrome causes hypogonadism and azoosper-
mia in >90% cases (Stahl et al., 2010, Bedaiwy and Botros, 2014).
Testicular injury may also result in irreparable damage to the testicular
tissue leading to infertility (Stahl et al., 2010). A recent study has high-
lighted the relevance of attempting salvage, even in cases of subject-
ively dead testicle, and to offer the patient FP options (Woodruff et al.,
2010).
Gender reassignment procedures
Removal of testicles or ovaries destroys the ability to have genetically-
related children, while feminizing/masculinizing medications used in
gender reassignment procedures may lead to diminished fertility
(Darney, 2008). The World Professional Association for Transgender
Health has emphasized the need to discuss and provide counselling
about FP and fertility treatment ‘before starting hormone therapy or
undergoing surgery to remove/alter their reproductive organs’ even at
a younger age (Coleman et al., 2012). Further, the Endocrine Society
recommends providing counsel about FP ‘prior to initiation of puberty
suppression in adolescents and before treatment with sex hormones
of the desired sex in both adolescents and adults’ (Hembree et al.,
2009). Evidence regarding reproductive health issues in individuals
receiving treatments for gender dysphoria is scarce. Currently, there
are no established techniques for preserving gonadal function in pre-
pubertal or pubertal adolescents, who will never develop reproductive
function in their natal sex owing to blockers or cross-gender hormones
(Coleman et al., 2012). There is an ongoing ethical debate on whether
FP should or should not be offered to transgender individuals (De
Wert et al., 2014).
Delayed childbearing
Female fertility decreases gradually but signiﬁcantly after age 32 years,
and faster after 37 years, which compromises fertility when delaying
childbearing (The ACOG Committee on Gynecologic Practice, 2014).
This is important, since an increasing proportion of couples in devel-
oped countries choose to have children later in life (≥35 years). Given
that delaying childbearing is considered a non-medical indication for
FP, the term ‘AGE banking’ (oocyte banking for anticipated gamete
exhaustion) has been proposed for oocyte cryopreservation in these
cases (Stoop et al., 2014).
Available procedures for FP
The most recent practice guidelines issued for cancer patients by the
ASRM (Ethics Committee of ASRM, 2013) and the American Society
of Clinical Oncology (Loren et al., 2013) provide an exhaustive review
of all evidence supporting currently available FP procedures, which
may be adaptable to all scenarios where fertility may be compromised.
Women
Both, embryo and oocyte cryopreservation (slow freezing or vitriﬁcation)
are ﬁrst-line FP methods (Fig. 1). However, oocyte cryopreservation is
increasingly preferred in adolescent girls or young women without a life
partner given that it overcomes religious, ethical or practical issues
related to embryo storage (Bedoschi and Oktay, 2013; Loren et al.,
2013). Mature oocyte vitriﬁcation is preferred in post-pubertal women
when gonadotoxic treatment can be delayed to allow time for controlled
ovarian stimulation (COS) (Cobo et al., 2013). Harvesting of immature
oocytes by aspiration would be an option for patients unable to undergo
COS such as pre-pubertal girls, women with aggressive or hormone-
sensitive cancers, or those with polycystic ovary syndrome (Kim et al.,
2016). The beneﬁts of adding tamoxifen or letrolozole to COS regimens
administered to women with breast cancer are still unclear (Dahhan
et al., 2014). IVM has been shown to improve outcomes in breast cancer
patients undergoing COS for FP (Oktay et al., 2010).
Ovarian tissue cryopreservation (OTC) is a COS-independent
experimental technique which also allows immediate cancer treatment,
and iscurrently the only FP option in paediatric patients (Donnez and
Dolmans, 2013) and in hormone-dependent diseases (Kim et al., 2016).
Reimplantation of this tissue either in the pelvic cavity (orthotopic) or
elsewhere (heterotopic) has the potential of restoring fertility and ovar-
ian hormone secretion. Reimplantation of frozen–thawed ovarian tissue
in the pelvic cavity is usually carried out by laparoscopy, but the surgical
technique is contingent on the presence (or not) of at least one ovary. If
an ovary is present, the remaining atrophic cortex is removed using scis-
sors, thereby creating a grafting bed onto which the thawed ovarian frag-
ments are placed. If no ovaries remain, the ovarian pieces are placed in
a peritoneal window created in the peritoneum of the broad ligament,
in an area where retroperitoneal capillaries are visible (Donnez et al.,
2012).
Ovarian tissue could also be preserved as an entire ovary with its vas-
cular pedicle, preventing ischaemic damage occurring between trans-
plantation and revascularization (Donnez et al., 2005). Fertility
restoration after whole ovary preservation requires retransplantation of
the whole organ accompanied by vascular anastomoses of the blood
vessels. However, although recent evidence from large animals, such as
sheep, suggests that natural fertility can be fully restored following auto-
transplantation of whole ovaries and their supporting vascular pedicle
after slow freezing and thawing (Onions et al., 2013, Campbell et al.,
2014), cryopreservation of the whole ovary is likely to be more prob-
lematic in adult women owing to the increased size of their ovaries, the
difﬁculty of achieving adequate perfusion and penetration of the
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cryoprotectants agents through the whole organ, and the inherently dif-
ferent freezing and thawing optima for the different cell types in both
the ovary and blood vessels. Although several methods have been
developed to help overcome these barriers (Bedaiwy et al., 2006;
Onions et al., 2013; Campbell et al., 2014; Martínez et al., 2014), more
research is needed before this technique can be translated into clinical
practice.
Fertoprotective agents
GnRH analogues/agonists (GnRHa) may protect follicles from destruction
during chemotherapy, probably by suppression of gonadotrophin levels
and reduction of utero-ovarian perfusion (Meirow et al., 2007). These
agents have long been used for the prevention of ovarian damage, despite
their efﬁcacy being a subject of debate owing to inconsistent results from
randomized trials using GnRHa (Badawy et al., 2009; Sverrisdottir et al.,
2009; Del Mastro et al., 2011; Gerber et al., 2011; Munster et al., 2012;
Demeestere et al., 2013; Elgindy et al., 2013; Moore et al., 2015). Two
meta-analyses of randomized trials have found an overall signiﬁcant
reduced risk of POI in young breast cancer patients (Del Mastro et al.,
2014; Lambertini et al., 2015). GnRHa increased the pregnancy rate and
had no negative impact on prognosis (Lambertini et al., 2015). This pro-
tective effect was not as clear in other cancer patients (ovarian and lymph-
oma) (Del Mastro et al., 2014). Recently, no protective effect at all was
found in young patients with lymphoma (Demeestere et al., 2016). Still,
the quality of evidence is relatively low given the number of women
included, relatively short-term follow-up hitherto and signiﬁcant hetero-
geneity. Further high quality studies are needed to study the (long-term)
effects of GnRHa use on POI.
Men
Sperm cryopreservation is the only established FP method in adult and
adolescent males. Alternatives to the procurement of semen samples by
masturbation include assisted ejaculation methods such as penile vibratory
stimulation or electroejaculation. A recent paper on the European
PATIENT SEMEN ANALYSIS TESTICULAR
BIOPSY
INTRA-OPERATIVE
ANALYSIS
METHOD OF
CRYOPRESERVATION
Pre-Pubertal
Biopsy with NO
intra-operative
analysis
No sperm/
sperm unlikely*
Sperm detected/
Sperm likely*
Immature testis
protocol
Semen Storage
protocol
Immature testis
protocol
+
Mature testis protocol
Unable to produce
sperm (eg <12)
Unsuitable for semen
cyropreservation
Oligozoospermia/
Azoospermia
or
Pubertal
Suitable for semen
cyropreservation
Biopsy with
intra-operative
analysis
Figure 1 Algorithm for the cryopreservation of testicular tissue/sperm in pre-pubertal and adolescent patients at high risk of infertility. Clinical
assessment for puberty should be carried out by a clinician with experience in pubertal assessment. It must be stressed that no clinical parameter can
accurately predict the presence of sperm. The proven treatment option for pubertal and adolescent boys who are considered capable of producing a
semen sample is semen collection and cryopreservation. If sufﬁcient sperm are recovered the gametes can be banked using commercial glycerol-based
sperm cryomedia. For those young patients who are clinically pre-pubertal and for whom semen cryopreservation is not possible the fertility preserva-
tion strategy should include collection of a testicular biopsy by an experienced surgeon. The tissue should be cryopreserved with a protocol optimized
for preserving immature germ cells, (immature testis protocol). Patients who are pubertal but are unable to produce a suitable semen sample may pro-
ceed to testicular biopsy, with intra-operative analysis. Techniques for intra-operative analysis may vary between institutions but should be aimed at
identifying tissue containing (or likely to contain) sperm. This should be carried out by an individual with experience in analysis of testicular tissue (e.g.
surgeon, embryologist or andrologist). When sperm are not identiﬁed or deemed unlikely the tissue should be frozen with the immature testis protocol
used for pre-pubertal patients. For patients in whom sperm are identiﬁed or considered likely to be present, tissue should be split into two portions for
storage. One portion should be cryopreserved using the immature testis preservation protocol, whilst the second portion should be stored using a
protocol aimed at preserving mature sperm cells with glycerol as the main cryoprotectant. As stated in the text at present there are several protocols
for cryopreservation of immature testicular tissue and there is no clear evidence at the time of writing to demonstrate which is optimal. Reprinted with
permission from Picton et al. (2015).
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perspective on testicular tissue cryopreservation for FP in pre-pubertal
and adolescent boys by the ESHRE Task Force on Fertility Preservation
for severe diseases recommends an algorithm for sperm and testicular tis-
sue cryopreservation in pre-pubertal boys and adolescent males at high
risk of fertility loss (Picton et al., 2015). This algorithm includes alternative
experimental techniques, such as testicular sperm extraction (TESE), for
patients presenting oligo- or azoospermia at the time of cryopreservation
or those with necrozoospermia or ejaculation disorders, or immature tes-
ticular tissue cryopreservation or SSC cryopreservation when no sperm
can be collected (Fig. 1).
Results of ART after FP
Women
As a well-established technology, embryo cryopreservation has high
pregnancy success rates (Bedoschi and Oktay, 2013). However, out-
comes in cancer patients are scarce. Recently, Dolmans et al. (2015)
reported a 44% live birth rate (LBR) per patient among 54 women
with cancer undergoing IVF and embryo cryopreservation, with a cumu-
lative live birth rate (CLBR) similar to that achieved with fresh embryos
in non-cancer patients (Table II). Similarly, Oktay et al. reported 18
pregnancies and 25 live births among 33 women with breast cancer,
with a LBR of 45% per embryo transfer (Oktay et al., 2015). Success
rates associated with oocyte cryopreservation have signiﬁcantly
improved in recent years, with vitriﬁcation success rates being superior
to slow freezing (Cil et al., 2013). A recent report of the outcomes
achieved in oocyte donation showed a 6.5% oocyte-to-baby rate, with
CLBR increasing with the number of oocytes used (Cobo et al., 2015).
A similar report among women undergoing oocyte vitriﬁcation
because of age or because of non-oncological medical conditions
revealed a LBR per patient of 50% among women aged ≤35 years, and
of 22.9% among those aged >36 years after the transfer of embryos
obtained from vitriﬁed oocytes. The CLBR was higher and increased
faster among younger women (Cobo et al., 2016) (Table II). It should
be noted that these ﬁgures arise from patients with a good prognosis
who are managed by a highly experienced team, and therefore may
not be representative of other FP programmes (Stoop, 2016). These
success rates are comparable to those achieved with fresh oocytes
(Rienzi et al., 2010; Solé et al., 2013). Outcomes after oocyte vitriﬁca-
tion among female cancer patients are scarce. Martinez et al. (2014)
reported fertilization rates up to 76.6% and a mean number of
embryos transferred of 1.8 ± 0.7 SD among 11 women with cancer,
four of whom gave birth at term without negative perinatal outcomes.
Alvarez et al. (2014) ﬁrst reported a successful birth in a woman with
invasive ovarian cancer.
Despite being considered an experimental technique both restor-
ation of ovarian function and spontaneous pregnancies after ART have
been reported after orthotopic transplantation of cryopreserved ovar-
ian tissue (Demeestere et al., 2015; Donnez and Dolmans, 2015;
Jensen et al., 2015; Oktay et al., 2016). Only one case of a live birth
after heterotopic transplantation has been reported up to 2013 (Stern
et al., 2013). Recently, Demestree et al. have reported the ﬁrst live
birth following re-grafting of ovarian tissue that had been cryopre-
served during childhood in a 13-year old girl undergoing HSCT
(Demeestere et al., 2015). To date, a large series of 60 live births after
transplantation of cryopreserved ovarian tissue has been reported,
also showing that by repeating the procedure ovarian activity can be
restored for more than 11 years (Donnez and Dolmans, 2015). In a
series of 111 cases, the conception rate was 29%. Two women deliv-
ered three babies each, proving the efﬁcacy of the technique, as well
as the possibility of conceiving naturally several times after only one
transplantation procedure (Donnez et al., 2015; Jensen et al., 2015).
Although it is impossible to provide a ﬁxed success rate for transplant-
ation of ovarian tissue as long as it remains active (Andersen, 2015),
given these encouraging results, ovarian cortex transplantation is pro-
posed as an open clinical application (Donnez et al., 2015).
Men
Success rates of semen cryopreservation have greatly increased with
advances in ART, especially in ICSI, with pregnancy rates up to 57%
(Picton et al., 2015). With this technique, Garcia et al. (2015) reported
a LBR of 62.1% in a cohort of 272 men with cancer, which was signiﬁ-
cantly higher than that of the comparative normospermic non-cancer
.............................................................................................................................................................................................
Table II Clinical outcomes from fertility preservation techniques in women.
Author FP technique Women/Indication Outcome
Dolmans et al. (2015) Embryo
cryopreservation
54/Cancer
33 returned/20 ET
22% LBR per ET
Nine pregnancies
Four deliveries
Oktay et al. (2015) Embryo
cryopreservation
33/Breast cancer
18 returned/55 ET
45% LBR per ET
26 pregnancies
18 deliveries
Cobo et al. (2015) Oocyte vitriﬁcation Ovum donation programme 6.5% oocyte-to-baby rate.
CLBR increased with the number of oocytes used
Cobo et al. (2016) Oocyte vitriﬁcation Delaying childbearing or non-oncological medical
conditions
50% LBR per patient in women ≤35 years old
22.9% LBR per patient in women >36 years old
Donnez et al. (2015) Ovarian tissue
cryopreservation
N = 111 cases, 32 conceived
29.0% LBR per patient
FP, fertility preservation; ET, embryo transfer; LBR, live birth rate; CLBR, cumulative live birth rate.
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population. To date, no clinical outcomes have been reported with
other FP techniques.
Future perspectives
Fig. 2 summarizes all FP techniques that are currently under study.
Women
Activation of ovarian follicles
Cryopreserved ovarian tissue from prepuberal patients and patients
with primary POI contains immature primordial follicles that must be
activated in order to start developing. It has been recently described
that activation of primordial follicles can be induced in vivo by mechan-
ically interrupting the Hippo signalling pathway (by ovarian fragmenta-
tion, drilling, laser) (Hsueh et al., 2015). Follicle activation may also be
achieved in vitro before autotransplantation by acting on the PI3K-
PTEN-AKT-FOXO3 pathway [phosphatidylinositol 3-kinase(PI3K)
activators and phosphatase and tensin homologue enzyme (PTEN)
inhibitors, Protein Kinase B (AKT) stimulators, transcriptional factor
forkhead box O3(FOXO3)] which has been shown to regulate prim-
ordial follicle dormancy at oocyte level (Hsueh et al., 2015). This
pathway has also a fundamental role in FSH stimulation of granulosa
cell differentiation of antral follicles and in oocyte maturation of preo-
vulatory follicles (Hsueh et al., 2015). Using this double approach in
women with POI, Kawamura et al. (2013) found rapid follicle growth
after grafting ovarian tissue back to patients, obtaining mature eggs. A
live birth was achieved after IVF and embryo transfer. In vitro activation
protocols are under development with the aim of increasing the pool of
viable activated follicles available for in vitro growth (IVG) procedures
(Novella-Maestre et al., 2015).
In vitro follicle culture
Transplantation of cryopreserved tissue carries the risk of re-seeding
original cancer cells into the patient, as recently highlighted in a series
of recent reviews and reports (Ernst et al., 2013; Rosendahl et al.,
2013; Stern et al., 2013; Dolmans et al., 2013a, 2013b; Sorensen et al.,
2014; Yding Andersen et al., 2014). This risk can be minimized by using
complete IVG and maturation of oocytes as the means of fertility res-
toration (Picton et al., 2008; Smitz et al., 2010). The goal of complete
IVG and maturation of oocytes is particularly challenging in human folli-
cles because of the greatly extended developmental time-frame for fol-
licles and oocytes, and increased size of ovulatory follicles and mature
gametes (Telfer and Zelinski, 2013). Furthermore, recent evidence
Ovary
Mature oocyte* Inmature oocyte
IVM
IVF/ICSI
Embryo* 
Embryo Transfer
Live birth
OT  transplant
(ortho- or heterothopic)
Ovarian tissue* 
In vitro follicle culture* 
Ovarian tissue supporting
follicular growth
Follicle depleted ovary
Artificial ovary
Isolation of 
oogonial stem cells
Embryonic stem cells
Induced pluripotent
stem cells
Differentiation
Into somatic cells
+Into oocytes
In vitro follicle differentiation 
Whole ovary*
Follicle activation
Figure 2 Fertility preservation techniques in women. Experimental procedures are indicated in discontinuous boxes, while established ones (i.e.
those proven to restore fertility, with live births reported) are indicated in shaded boxes. Vitriﬁed-thawed oocytes can be fertilized by IVF/ICSI for
embryo transfer. Immature oocytes can be matured in vitro (IVM) for IVF/ICSI. Research is undergoing on the potential use of oogonial stem cells to
repopulate follicle-depleted ovaries or differentiating follicle somatic cells and oocytes from embryonic stem cells or induced pluripotent stem cells to
assemble de novo follicles for transplantation or IVM and IVF/ICSI. *Cryopreserved. OT, ovarian tissue.
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suggests that the dynamics of the in vivo and hence in vitro growth
environments may differ between the pre- and post-pubertal human
ovary (Anderson et al., 2014).
To date, three-dimensional (3D) culture methods have proved
most successful in supporting the demands of human follicle activa-
tion and IVG, as these approaches are best able to maintain the
morphology of the follicles and preserve critical cell–cell interactions
both between the different cellular compartments in the follicle and
between the follicle and its surrounding stromal tissue thus better
mimicking the in vivo ovarian growth environment. Several multi-step
culture systems have succeeded in culturing human follicles (Newton
et al., 1999; Picton et al., 2008; McLaughlin and Telfer, 2010; Barrett
et al., 2010; Skory et al., 2015). Critically, all IVG systems used for
fertility restoration for FP patients must start with the in situ culture
of primordial follicles from cryopreserved tissue. The recent produc-
tion of meiotically competent metaphase II non-human primate and
human oocytes following IVG of freshly isolated secondary follicles
(Xu et al., 2011; Xiao et al., 2015) is encouraging. However, whether
mature human oocytes can be obtained from primordial follicles
grown from cryopreserved ovarian tissue using these culture strategies
or whether the oocytes so derived are competent to complete cytoplas-
mic and nuclear maturation in a timely manner is yet to be conﬁrmed. It
also remains to be conﬁrmed whether their genomic imprint establish-
ment and maintenance is normal (Anckaert et al., 2013) and whether
metaphase II gametes so produced are healthy and able to undergo fertil-
ization and support normal early embryonic development until the
embryonic genome is activated. Considerable further research effort is
therefore needed to conﬁrm the safety and efﬁcacy of oocytes derived
following extended IVG and the maturation of human oocytes from cryo-
preserved tissue before this technology can be used to restore fertility in
FP patients.
Artiﬁcial ovaries
An alternative to the in vitro culture of primordial follicles is their devel-
opment into an engineered ‘artiﬁcial ovary’, consisting of isolated pre-
antral follicles along with other ovarian cells assembled in a structure-
3D matrix, or scaffold, which allow follicles to grow and develop in an
ovarian-like environment (Luyckx et al., 2014; Vanacker et al., 2014).
Ovarian cells from fresh medullary tissue have been suggested as the
best source of isolated stromal cells for the artiﬁcial ovary (Soares
et al., 2015). Once transplanted to the patient, this artiﬁcial ovary
would potentially restore fertility and endocrine function (Kim et al.,
2016). Following this procedure, Laronda et al. (2015) reported the
production of estradiol in vitro by primary ovarian cells of mice seeds
into a previously decellularized ovary. Moreover, when transplanted
into ovariectomized mice, grafts from these cells were able to initiate
puberty.
New fertoprotective agents
The most recent theory of chemotherapy-induced follicle loss sug-
gests that, simultaneously with large follicle apoptosis, chemotherapy
also triggers activation of dormant follicle growth. Current research
focuses thus on both agents with anti-apoptotic properties (imatinib,
sphingosine-1-phosphate, thyroid hormone T3, granulocyte colony-
stimulating factor and tamoxifen) that have been shown to reduce
follicle loss in animal models (Kim et al., 2016),and on agents that
also prevent follicle activation such as AS101, an immune modulator
that acts on the PI3K/PTEN/AKT follicle activation pathway (Kalich-
Philosoph et al., 2013), and anti-Mullerian hormone (Roness et al.,
2016). Clinical applicability of these agents depends not only on their
fertoprotective capacity, but also on their potential interaction with
cancer treatments.
Men
In a similar way, the risk of reintroducing malignant cells via the graft
might be overcome by in vitro spermatogenesis. As per follicle culture,
SSCs (whole testicular biopsy or isolated SSCs) are cultured in 3D sys-
tems that resemble the in vivo situation (Picton et al., 2015). Recently,
Nickkholgh et al. have reported the genetic stability of a long-term cul-
ture of human SSCs from two prostate cancer patients and although
changes in the methylation status were observed, the consequences of
these epigenetic changes on the functionality of the sperm of the
health of the offspring are unknown (Nickkholgh et al., 2014). The fer-
tilizing ability of in vitro-cultured sperm is to be established before
assessing the clinical value of this technique. Moreover, fertility restor-
ation strategies by autotransplantation of cryopreserved testicular tis-
sue have not yet been tested for safe clinical use in humans (Picton
et al., 2015).
Both sexes
Artiﬁcial gametes
To date, infertile patients lacking functional oocytes or sperm cannot
beneﬁt from currently available ART unless donor gametes are used.
The use of primordial germ cells (PGC) present in the gonads, such as
SSC, is a promising approach for treating infertility. However, the
population of these cells is scarce and decreases with age. Pluripotent
stem cells (PSC), such as embryonic stem cells or induced PSC, consti-
tute other potential sources of gametes (Vassena et al., 2015).
Hayashi and Saitou (2013) derived functional PGCs from PSC
potentially able to generate functional oocytes and sperm (Vassena
et al., 2015). Recently, Zhou et al. (2016) have reported the gener-
ation of haploid mouse spermatid-like cells able to produce viable and
fertile offspring. Notwithstanding these advances, a recent critical
review of available evidence in humans and animal models carried out
by the ESHRE Special Interest Group in Stem Cells concluded that ‘to
date there are no proven stem cell-based means to improve repro-
ductive function, either by producing functional gametes in vitro, or
stimulating the resident stem cell population in the ovary to elicit de
novo oocyte production’ (Vassena et al., 2015).
Summary
The Expert Working Group made the following recommendations:
• Several oncological and non-oncological diseases may affect current
or future fertility, either due to the disease itself or to gonadotoxic
treatment, and need an adequate FP approach. These patients
should be counselled regarding potential fertility loss and should be
referred to fertility specialists to discuss options for FP and current
results.
• Women wishing to postpone maternity and transgender individuals
before starting hormone therapy or undergoing surgery to remove/
alter their reproductive organs, should also be counselled
accordingly.
1809Update on fertility preservation from the Barcelona 2015 expert meeting
• Embryo and oocyte cryopreservation are ﬁrst-line FP methods in
post-pubertal women. Metaphase II oocyte cryopreservation (vitri-
ﬁcation) is the preferred option.
• Cumulative evidence of restoration of ovarian function and spon-
taneous pregnancies after ART following orthotopic transplantation
of cryopreserved ovarian tissue supports its future consideration as
an open clinical application.
• Semen cryopreservation is the only established FP technique in
men.
• Testicular tissue cryopreservation should be recommended in pre-
pubertal boys even though fertility restoration strategies by auto-
transplantation of cryopreserved testicular tissue have not yet been
tested for safe clinical use in humans.
• The establishment of international registries on the short- and long-
term outcomes of FP techniques is strongly recommended.
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